Breaking News Instant updates and real-time market news.

RHHBY

Roche

$30.26

0.04 (0.13%)

, ABBV

AbbVie

$96.47

0.52 (0.54%)

07:37
12/12/17
12/12
07:37
12/12/17
07:37

Genentech says Venclexta, Rituxan reduces risk of disease progression or death

Genentech, a member of the Roche Group (RHHBY), announced the first results from the pivotal Phase III MURANO study evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan for the treatment of people with relapsed or refractory chronic lymphocytic leukemia. The results showed that a fixed duration of treatment with Venclexta plus Rituxan significantly reduced the risk of disease progression or death by 83% compared with BR. No new safety signals were observed. Venclexta is being developed by AbbVie (ABBV) and Genentech, a member of the Roche Group. It is jointly commercialized by the companies in the United States and commercialized by AbbVie outside of the United States. Data from the MURANO study will be submitted to global health authorities, including the U.S. Food and Drug Administration, which has granted Breakthrough Therapy Designation for Venclexta in combination with Rituxan for the treatment of relapsed or refractory CLL based on promising results from the Phase Ib M13-365 study. Venclexta was granted accelerated approval by the FDA in April 2016 for the treatment of people with CLL with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. The MURANO study is part of the company's commitment in the United States to convert the current accelerated approval of Venclexta to a full approval. MURANO is a Phase III open-label, international, multicenter, randomized study evaluating the efficacy and safety of Venclexta in combination with Rituxan compared to bendamustine in combination with Rituxan. All treatments were of fixed duration. The study included 389 patients with relapsed or refractory chronic lymphocytic leukemia who had been previously treated with at least one, but not more than three, lines of therapy. Patients were randomly assigned in a 1:1 ratio to receive either Venclexta plus Rituxan or BR. The primary endpoint of the study is investigator-assessed progression-free survival. Secondary endpoints include PFS assessed by independent review committee, overall response rate, complete response rate, overall survival, minimal residual disease status, duration of response, event-free survival and time to next CLL treatment.

RHHBY

Roche

$30.26

0.04 (0.13%)

ABBV

AbbVie

$96.47

0.52 (0.54%)

  • 23

    Dec

  • 23

    Feb

RHHBY Roche
$30.26

0.04 (0.13%)

11/22/17
COWN
11/22/17
NO CHANGE
Target $105
COWN
Outperform
Impressive Venclexta abstract positive for AbbVie, says Cowen
Cowen analyst Steven Scala said a late breaking ASH abstract showed impressive data for AbbVie's Venclexta drug used in chronic lymphocytic leukemia. The analyst has modeled $2.6N in sales in 2024 and company guidance suggests sales could reach $6B in 2025. Scala reiterated his Outperform rating and $105 price target on AbbVie shares.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
12/07/17
JPMS
12/07/17
NO CHANGE
JPMS
Overweight
Roche to outperform on 'very strong' lung cancer data, says JPMorgan
JPMorgan analyst Richard Vosser says Roche reported "very strong" detailed progression free survival data from its IMPower150 lung cancer study. At the conference later today, the analyst expects to see strong interim overall survival data. He expects the shares to outperform by 1%-2% following this morning's data. Vosser has an Overweight rating on Roche.
12/07/17
PIPR
12/07/17
NO CHANGE
PIPR
Roche lung cancer data underwhelming versus Merck's, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss says that while Roche's (RHHBY) IMpower150 data are strong and suggesting a likelihood that the combination of Tecentriq with Avastin and chemo will be approved in non-small cell lung cancer, the data also appear underwhelming compared to Merck's (MRK) KN-21G trial data. The analyst does expect Tecentriq approval in lung cancer next year and reiterates an Overweight rating on Roche. Whether KN-021G represents the "high water mark" for efficacy can only be answered following full presentation of the remaining pivotal Phase 3 trials in this setting, and until then confusion is likely to remain, Purkiss tells investors in a research note. Merck in premarket trading is up 85c to $55.20 while Roche is down 93c to $30.40.
ABBV AbbVie
$96.47

0.52 (0.54%)

11/24/17
DBAB
11/24/17
NO CHANGE
Target $59
DBAB
Hold
Deutsche cuts Merck target to $59 on competition from AbbVie, GSK
Deutsche Bank analyst Gregg Gilbert lowered his price target for Merck (MRK) to $59 from $62 citing expectations for more competitive pressure on Zepatier and Zostavax. The stock closed Wednesday up 10c to $54.37. Demand trends for Merck's hepatitis C virus drug Zepatier have continued to decline as AbbVie's (ABBV) Mavyret has gained traction, Gilbert told investors in a research note. The analyst also assumes "significant pressure" on Merck's shingles vaccine Zostavax from the near-term competitive launch of GlaxoSmithKline's (GSK) Shingrix. Gilbert views Merck's risk/reward as fairly balanced and he keeps a Neutral rating on the shares.
12/04/17
BMOC
12/04/17
INITIATION
Target $31
BMOC
Outperform
InflaRx initiated with an Outperform at BMO Capital
BMO Capital analyst M. Ian Somaiya initiated InflaRx (IFRX) with an Outperform rating and a price target of $31. Somaiya says the positive Phase 2a data for the company's IFX-1 and regulatory path established by AbbVie's (ABBV) Humira de-risk the opportunity in hidradenitis suppurativa skin disorder, supporting his expectations for a positive Phase 2b data in the first half of FY19.
12/05/17
DBAB
12/05/17
NO CHANGE
Target $82
DBAB
Buy
Deutsche views Neurocrine's elagolix program as underappreciated
Deutsche Bank analyst Andrew Peters says that while the Ingrezza launch continues to be the primary focus for Neurocrine (NBIX) investors, the company's AbbVie-partnered (ABBV) elagolix program remains an "underappreciated aspect of the overall investment thesis." The analyst remains confident in the potential commercial opportunity for elagolix with data from the Phase 3 uterine fibroid study expected in early 2018 and the regulatory review in endometriosis ongoing. Recent expert checks have largely supported elagolix, Peters tells investors in a research note. The analyst raised his price target for Neurocrine shares to $82 from $79 and reiterates a Buy rating on the name.
12/05/17
LEER
12/05/17
NO CHANGE
Target $106
LEER
Outperform
AbbVie Risankizumab may be best in class for Psoriasis, says Leerink
Leerink analyst Geoffrey Porges notes that AbbVie reported positive data from the 4th of its four phase III trials that make up its pivotalprogram for its IL-23 antibody Risankizumab in patients with moderate-severe plaque psoriasis. The analyst believes risankizumab has a clearly differentiated profile in comparison to existing anti-TNF and IL-17s, making this an attractive option for use prior to other biologics once it becomes approved. Additionally, it appears risankizumab may offer incremental advantages over IL-23 competitor Tremfya in terms of efficacy and dosing schedule. He reiterates an Outperform rating and $106 price target on the shares.

TODAY'S FREE FLY STORIES

BY

Byline Bancorp

$21.33

0.02 (0.09%)

18:51
10/17/18
10/17
18:51
10/17/18
18:51
Hot Stocks
Byline Bancorp to acquire Oak Park River Forest Bankshares for $42M »

Byline Bancorp and Oak…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

ABB

ABB

$21.37

-0.115 (-0.54%)

18:48
10/17/18
10/17
18:48
10/17/18
18:48
Periodicals
ABB weighs divesting $10B power grid business, Bloomberg reports »

ABB is working with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEC

Vectrus

$28.98

-0.74 (-2.49%)

18:22
10/17/18
10/17
18:22
10/17/18
18:22
Hot Stocks
Vectrus names Kevin Boyle chief legal officer »

Vectrus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$6.41

-0.005 (-0.08%)

18:21
10/17/18
10/17
18:21
10/17/18
18:21
Hot Stocks
Sprint extends credits to Florida customers impacted by Hurricane Michael »

Sprint said it continues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TALO

Talos Energy

$29.85

-1.49 (-4.75%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Talos Energy reaches pact with Hokchi to cross-assign interests »

Talos Energy Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:05
10/17/18
10/17
18:05
10/17/18
18:05
Hot Stocks
Steel Dynamics CEO says 'delivered a tremendous third quarter performance' »

"The team delivered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:02
10/17/18
10/17
18:02
10/17/18
18:02
Hot Stocks
Steel Dynamics CEO: We believe steel consumption will continue to be strong »

"We remain confident…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

STLD

Steel Dynamics

$40.55

0.29 (0.72%)

18:01
10/17/18
10/17
18:01
10/17/18
18:01
Earnings
Steel Dynamics reports Q3 adjusted EPS $1.69, consensus $1.64 »

Reports Q3 revenue $3.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CRTO

Criteo

$23.00

-0.29 (-1.25%)

, RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

17:44
10/17/18
10/17
17:44
10/17/18
17:44
Periodicals
Advertising technology firm DataXu exploring sale, WSJ says »

DataXu, which offers…

CRTO

Criteo

$23.00

-0.29 (-1.25%)

RUBI

Rubicon Project

$3.77

-0.06 (-1.57%)

FUEL

Rocket Fuel

$0.00

(0.00%)

GOOG

Alphabet

$1,115.99

-4.12 (-0.37%)

FB

Facebook

$159.46

0.65 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 15

    Nov

  • 16

    Nov

  • 03

    Mar

BTU

Peabody Energy

$36.09

-0.31 (-0.85%)

17:37
10/17/18
10/17
17:37
10/17/18
17:37
Hot Stocks
Peabody Energy increases quarterly dividend nearly 4% to 13c per share »

Peabody Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:34
10/17/18
10/17
17:34
10/17/18
17:34
Earnings
Brandywine Realty sees FY19 FFO $1.37-$1.47, consensus $1.44 »

Sees FY17 EPS 36c-46c,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:33
10/17/18
10/17
17:33
10/17/18
17:33
Earnings
Brandywine Realty narrows FY18 FFO view to $1.36-$1.40 from $1.35-$1.41 »

Consensus for FY18 FFO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BDN

Brandywine Realty

$14.56

-0.11 (-0.75%)

17:32
10/17/18
10/17
17:32
10/17/18
17:32
Earnings
Brandywine Realty reports Q3 FFO 35c, consensus 35c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

BPRN

Bank of Princeton

$30.75

-0.16 (-0.52%)

17:32
10/17/18
10/17
17:32
10/17/18
17:32
Hot Stocks
Bank of Princeton declares initial cash dividend of 3c per share »

This dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$32.01

-0.25 (-0.77%)

, AMZN

Amazon.com

$1,832.81

14.81 (0.81%)

17:26
10/17/18
10/17
17:26
10/17/18
17:26
Periodicals
eBay sues Amazon, claims sellers were illegally poached, WSJ says »

eBay (EBAY) has filed a…

EBAY

eBay

$32.01

-0.25 (-0.77%)

AMZN

Amazon.com

$1,832.81

14.81 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 25

    Oct

  • 30

    Oct

  • 03

    Mar

OIS

Oil States

$29.77

-0.13 (-0.43%)

17:18
10/17/18
10/17
17:18
10/17/18
17:18
Earnings
Oil States sees Q3 revenue at low end of $273M-$298M, consensus $288.81M »

Oil States announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$45.90

-0.03 (-0.07%)

17:15
10/17/18
10/17
17:15
10/17/18
17:15
Periodicals
Intel 'shakes up' manufacturing unit amid production missteps, Oregonian says »

Sohail Ahmed, who has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

NOC

Northrop Grumman

$309.25

-2.87 (-0.92%)

17:15
10/17/18
10/17
17:15
10/17/18
17:15
Hot Stocks
Northrop Grumman awarded $697.03M Navy contract »

Northrop Grumman doing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:14
10/17/18
10/17
17:14
10/17/18
17:14
Hot Stocks
Crown Holdings CEO says Q3 performance 'solid' »

Commenting on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

PETQ

PetIQ

$34.46

-1.17 (-3.28%)

17:13
10/17/18
10/17
17:13
10/17/18
17:13
Hot Stocks
PetIQ announces strategic acquisition of HBH Enterprises »

PetIQ announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:10
10/17/18
10/17
17:10
10/17/18
17:10
Hot Stocks
Crown Holdings sees FY18 adjusted free cash flow approximately $625M »

Sees FY19 adjusted free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

ZS

Zscaler

$37.95

-1.11 (-2.84%)

17:09
10/17/18
10/17
17:09
10/17/18
17:09
Initiation
Zscaler initiated  »

Zscaler assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 10

    Dec

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:08
10/17/18
10/17
17:08
10/17/18
17:08
Hot Stocks
Breaking Hot Stocks news story on Crown Holdings »

Crown Holdings sees FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CCK

Crown Holdings

$47.64

-0.25 (-0.52%)

17:08
10/17/18
10/17
17:08
10/17/18
17:08
Earnings
Breaking Earnings news story on Crown Holdings »

Crown Holdings sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SYMC

Symantec

$20.57

-0.085 (-0.41%)

17:07
10/17/18
10/17
17:07
10/17/18
17:07
Initiation
Symantec initiated  »

Symantec assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.